To study the use of calcitriol in reducing protein in urine in patients with kidney damage due to proteinuria.

Phase 3

• Conditions: Health Condition 1: null- Chronic Proteinuric Nephropathy

• Registration Number: CTRI/2011/10/002086
• Lead Sponsor: ICMR

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 90

Inclusion Criteria

1.Normal blood pressure on stable doses of antihypertensive drugs for 1 month

2.Estimated GFR 30 -90 ml/min/1.73 m2

3.Children on corticosteroid should be on stable doses of corticosteroids for last 2 month

Exclusion Criteria

Following children will be excluded from the study.

1.Patients below 3 years of age

2.Patients with estimated GFR 30 ml/min/1.73m2

3.Patients with chronic liver disease or deranged transaminase levels (more than 2 times the normal)

4.Patients with phosphorus levels 5.5 mg/dl, current hypercalcemia (serum calcium 10.5 mg/dl) or untreated primary hyperparathyroidism.

5.Patients with hypercalciuria (24 h urinary calcium 4 mg/kg/d)

6.Children residing outside 200km of the Delhi border.

7.History of nephrolithiasis.

8.Known malabsorption syndromes, e.g., celiac disease, active inflammatory bowel disease, etc.

9.Treatment with vitamin D or any of its active metabolites in last 4 weeks

10.Treatment with any drug which may interfere with vitamin D metabolism, e.g., phenobarbital, phenytoin.

11.Patients with bilateral renal artery stenosis.

12.Patients on immunosuppressive drugs such as cyclophosphamide, calcineurin inhibitors, azathioprine

13.Steroid responsive nephrotic syndrome

14.Patients on high dose (2 mg/kg/d prednisolone or equivalent) or intravenous corticosteroids

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Degree of ProteinuriaTimepoint: at 0 and 6 months

Secondary Outcome Measures

Name	Time	Method
intact parathormone, 25OH vitamin D, highly selective C reactive protein, estimated Glomerular filtration rate, <br/ ><br>Carotid intimal medial thickness, Flow mediated dilatation of brachial artery, <br/ ><br>Occurence of hypercalcemia hyperposphatemiaTimepoint: at 0 and 6 months